V
Vindi Jurinovic
Researcher at Ludwig Maximilian University of Munich
Publications - 68
Citations - 2931
Vindi Jurinovic is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Medicine & Follicular lymphoma. The author has an hindex of 19, co-authored 56 publications receiving 2057 citations. Previous affiliations of Vindi Jurinovic include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.
Tobias Herold,Vindi Jurinovic,Chiara Arnreich,Brian J. Lipworth,Johannes C. Hellmuth,Michael von Bergwelt-Baildon,Matthias Klein,Tobias Weinberger +7 more
TL;DR: Maximal interleukin-6 levels before intubation showed the strongest association with the need of mechanical ventilation followed by maximal CRP, suggesting the possibility of using IL-6 or CRP levels to guide escalation of treatment in patients with COVID-19 related hyperinflammatory syndrome.
Journal ArticleDOI
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore,Vindi Jurinovic,Robert Kridel,Eva Hoster,Annette M. Staiger,Annette M. Staiger,Monika Szczepanowski,Christiane Pott,Nadja Kopp,Mark A. Murakami,Heike Horn,Heike Horn,Ellen Leich,Alden A. Moccia,Anja Mottok,Ashwini Sunkavalli,Paul Van Hummelen,Matthew D. Ducar,Daisuke Ennishi,Hennady P. Shulha,Christoffer Hother,Joseph M. Connors,Laurie H. Sehn,Martin Dreyling,Donna Neuberg,Peter Möller,Alfred C. Feller,Martin L. Hansmann,Harald Stein,Andreas Rosenwald,German Ott,Wolfram Klapper,Michael Unterhalt,Wolfgang Hiddemann,Randy D. Gascoyne,David M. Weinstock,Oliver Weigert +36 more
TL;DR: This work aimed to improve risk stratification of patients receiving first-line immunochemotherapy by integrating gene mutations into a prognostic model by establishing a clinicogenetic risk model that included the Follicular Lymphoma International Prognostic Index (FLIPI) and Eastern Cooperative Oncology Group (ECOG) performance status.
Journal ArticleDOI
Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling
Andreas Herbst,Vindi Jurinovic,Stefan Krebs,Susanne E. Thieme,Helmut Blum,Burkhard Göke,Frank T. Kolligs +6 more
TL;DR: DLD1 and SW480 colon carcinoma cell lines are suitable model systems to study Wnt/β- catenin signaling and associated colorectal carcinogenesis and the confirmed and the newly identified potential β-catenin target genes are useful starting points for further studies.
Journal ArticleDOI
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Vindi Jurinovic,Robert Kridel,Annette M. Staiger,Annette M. Staiger,Monika Szczepanowski,Heike Horn,Heike Horn,Martin Dreyling,Andreas Rosenwald,German Ott,Wolfram Klapper,Andrew D. Zelenetz,Paul M. Barr,Jonathan W. Friedberg,Stephen M. Ansell,Laurie H. Sehn,Joseph M. Connors,Randy D. Gascoyne,Wolfgang Hiddemann,Wolfgang Hiddemann,Michael Unterhalt,David M. Weinstock,Oliver Weigert,Oliver Weigert +23 more
TL;DR: The m7-FLIPI prospectively identifies the smallest subgroup of patients at highest risk of early failure of first-line immunochemotherapy and death, including patients not fulfilling the POD24 criteria, and should be evaluated in prospective trials of precision medicine approaches in FL.
Journal ArticleDOI
Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study
Zejuan Li,Tobias Herold,Chunjiang He,Peter J. M. Valk,Ping Chen,Vindi Jurinovic,Ulrich Mansmann,Michael D. Radmacher,Kati Maharry,Miao Sun,Xinan Yang,Hao Huang,Xi Jiang,Maria Cristina Sauerland,Thomas Büchner,Wolfgang Hiddemann,Abdel G. Elkahloun,Mary Beth Neilly,Yanming Zhang,Richard A. Larson,Michelle M. Le Beau,Michael A. Caligiuri,Konstanze Döhner,Lars Bullinger,Paul P. Liu,Ruud Delwel,Guido Marcucci,Bob Löwenberg,Clara D. Bloomfield,Janet D. Rowley,Stefan K. Bohlander,Jianjun Chen +31 more
TL;DR: A common prognostic gene signature composed of 24 genes was identified as an independent predictor of survival of patients with acute myeloid leukemia and the integrated risk classification incorporating this gene signature provides a better framework for risk stratification and outcome prediction than the ELN classification.